<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  A Novel Disinfection Method to Prevent Infection in Peritoneal Dialysis</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>12/01/2020</AwardEffectiveDate>
<AwardExpirationDate>08/31/2021</AwardExpirationDate>
<AwardTotalIntnAmount>255750.00</AwardTotalIntnAmount>
<AwardAmount>255750</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Henry Ahn</SignBlockName>
<PO_EMAI>hahn@nsf.gov</PO_EMAI>
<PO_PHON>7032927069</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to disrupt renal replacement therapy (RRT) by increasing access to peritoneal dialysis (PD). Over 500,000 kidney failure patients in the United States (US) require RRT each year, with only 52,000 patients receiving PD, despite it having a lower cost of care. PD adoption has been limited due to high rates of peritonitis, which occurs in over 30% of PD patients each year and is linked to 1 out of 6 PD patient deaths. This project will reduce the risk of infection in PD, providing current patients with safer care and enabling more RRT patients to receive PD. This would save the US healthcare system over $100 million annually in peritonitis-related hospitalizations. &lt;br/&gt;&lt;br/&gt;This Small Business Innovation Research (SBIR) Phase I project will evaluate the technical feasibility of delivering a safe, easy-to-operate internal tube disinfection protocol for PD to make it more practical in non-clinical settings. Existing efforts to prevent catheter-associated infections largely involve education and antimicrobial hub caps. However, education measures rely on patient compliance and antimicrobial caps leave catheter ends vulnerable to contamination when removed for treatment. This project aims to develop a device that demonstrates sufficient microbial disinfection within a connected PD system using an antimicrobial solution. Disinfection in a closed system eliminates the risk of secondary contamination events. However, significant concerns exist with regards to exposure of the patientâ€™s abdomen to the antimicrobial solution. To address this, rodent animal studies will be conducted to evaluate the acute systemic response and repeat exposure risk of antimicrobial residue to the peritoneal cavity. This study aims to demonstrate a sufficiently minimal toxicity risk compared to existing effects from dialysate solution use.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>11/24/2020</MinAmdLetterDate>
<MaxAmdLetterDate>11/24/2020</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2035898</AwardID>
<Investigator>
<FirstName>Sarah</FirstName>
<LastName>Lee</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Sarah Lee</PI_FULL_NAME>
<EmailAddress>sarah@relavomedical.com</EmailAddress>
<PI_PHON>7818203093</PI_PHON>
<NSF_ID>000821675</NSF_ID>
<StartDate>11/24/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>RELAVO, LLC</Name>
<CityName>BALTIMORE</CityName>
<ZipCode>212016512</ZipCode>
<PhoneNumber>7818203093</PhoneNumber>
<StreetAddress>300 W Pratt Street</StreetAddress>
<StreetAddress2><![CDATA[STE 200]]></StreetAddress2>
<CountryName>United States</CountryName>
<StateName>Maryland</StateName>
<StateCode>MD</StateCode>
<CONGRESSDISTRICT>07</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>MD07</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>106515098</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>RELAVO, LLC</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[Johns Hopkins Technology Ventures, Fast Forward]]></Name>
<CityName>Baltimore</CityName>
<StateCode>MD</StateCode>
<ZipCode>212051546</ZipCode>
<StreetAddress><![CDATA[1812 Ashland Avenue, Suite 110]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Maryland</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>07</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>MD07</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>5345</Code>
<Text>BIOMEDICAL ENGINEERING</Text>
</ProgramReference>
<Appropriation>
<Code>0121</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2021~255750</FUND_OBLG>
</Award>
</rootTag>
